GTXI GTx Inc.

7.83
-0.22  -3%
Previous Close 8.05
Open 7.98
Price To book 20.08
Market Cap 168673147
Shares 21,541,909
Volume 8,656
Short Ratio 2.75
Av. Daily Volume 37,444

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2, 2009.
Toremifene
Reduce fractures in men with prostate cancer
Noted August 14, 2017 that trial will not continue due to insufficient clinical benefit response (CBR).
Enobosarm
Breast cancer - advanced AR+ TNBC
Phase 2 data presented at International Continence Society Annual Meeting, September 13, 2017. Mean stress leaks decreased by 83% percent from baseline over 12 weeks. Phase 2 placebo trial has been initiated.
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)

Latest News

  1. GTx Announces Closing of $48.5 Million Private Placement
  2. GTx Announces $48.5 Million Private Placement
  3. GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
  4. GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
  5. GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
  6. GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
  7. GTx reports 2Q loss
  8. GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results
  9. GTx Discusses Key Goals with WSA
  10. GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
  11. Today's Research Reports on Stocks to Watch: Xbiotech and GTx
  12. GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
  13. GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results
  14. GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting
  15. GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics
  16. GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
  17. GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
  18. Is GTx, Inc. (GTXI) A Good Stock To Buy?